Understanding how certain blood cell mutations accelerate heart disease
Mechanisms and Modulation of Accelerated Atherosclerosis in Clonal Hematopoiesis
This study is looking at how certain changes in blood stem cells might raise the risk of heart disease as we get older, and it’s for anyone interested in understanding how inflammation affects heart health, with hopes of finding better treatments tailored to individual genetic needs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11017745 on NIH RePORTER |
What this research studies
This research investigates how specific mutations in blood stem cells, known as clonal hematopoiesis, can lead to an increased risk of cardiovascular disease as people age. The study focuses on the role of inflammatory signals, particularly IL-1 and IL-6, in promoting accelerated atherosclerosis, a condition characterized by the buildup of plaques in arteries. By using mouse models and analyzing human data, the researchers aim to explore targeted therapies that could reduce cardiovascular risks associated with these mutations. The ultimate goal is to develop personalized treatment strategies based on genetic profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research include older adults with clonal hematopoiesis mutations, particularly those with DNMT3A or TET2 mutations.
Not a fit: Patients without clonal hematopoiesis or those with other unrelated cardiovascular conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, targeted therapies that significantly reduce cardiovascular risks for patients with specific blood mutations.
How similar studies have performed: Previous research has shown promising results in targeting inflammatory pathways in cardiovascular disease, suggesting that this approach could be effective.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Libby, Peter — Brigham and Women's Hospital
- Study coordinator: Libby, Peter
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.